Chris Francis Sells 1,883 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences Ltd. (NASDAQ:WVE) insider Chris Francis sold 1,883 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $13.45, for a total transaction of $25,326.35. Following the transaction, the insider owned 61,867 shares in the company, valued at $832,111.15. The trade was a 2.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Chris Francis also recently made the following trade(s):

• On Friday, January 2nd, Chris Francis sold 9,375 shares of WAVE Life Sciences stock. The stock was sold at an average price of $16.03, for a total transaction of $150,281.25.
• On Monday, December 8th, Chris Francis sold 441,031 shares of WAVE Life Sciences stock. The shares were sold at an average price of $14.57, for a total transaction of $6,425,821.67.

WAVE Life Sciences Stock Down 3.5%

Shares of NASDAQ:WVE opened at $12.80 on Friday. The stock has a market cap of $2.14 billion, a PE ratio of -17.07 and a beta of -1.78. The company’s fifty day moving average is $15.09 and its 200 day moving average is $10.39. WAVE Life Sciences Ltd. has a 52 week low of $5.28 and a 52 week high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02). The business had revenue of $7.61 million for the quarter, compared to analysts’ expectations of $9.85 million. WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. Sell-side analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 EPS for the current year.

Institutional Investors Weigh In On WAVE Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of WVE. GSK plc bought a new stake in shares of WAVE Life Sciences during the 4th quarter valued at about $310,177,000. Adage Capital Partners GP L.L.C. lifted its holdings in WAVE Life Sciences by 20.0% in the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock worth $97,607,000 after buying an additional 2,500,000 shares during the period. Federated Hermes Inc. boosted its position in WAVE Life Sciences by 26.5% during the 4th quarter. Federated Hermes Inc. now owns 4,744,520 shares of the company’s stock valued at $80,657,000 after acquiring an additional 993,827 shares in the last quarter. 683 Capital Management LLC grew its holdings in shares of WAVE Life Sciences by 4.5% during the 2nd quarter. 683 Capital Management LLC now owns 4,100,000 shares of the company’s stock worth $26,650,000 after acquiring an additional 175,000 shares during the period. Finally, Primecap Management Co. CA grew its holdings in shares of WAVE Life Sciences by 115.7% during the 4th quarter. Primecap Management Co. CA now owns 4,095,282 shares of the company’s stock worth $69,620,000 after acquiring an additional 2,196,632 shares during the period. 89.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

WVE has been the subject of several recent research reports. Canaccord Genuity Group boosted their price objective on WAVE Life Sciences from $40.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, February 3rd. HC Wainwright upped their price target on shares of WAVE Life Sciences from $22.00 to $30.00 and gave the company a “buy” rating in a report on Friday, December 19th. Raymond James Financial reissued an “outperform” rating and set a $21.00 price target on shares of WAVE Life Sciences in a research report on Monday, December 8th. Wedbush boosted their price objective on shares of WAVE Life Sciences from $20.00 to $33.00 and gave the company an “outperform” rating in a research report on Friday, December 12th. Finally, Morgan Stanley set a $28.00 price objective on shares of WAVE Life Sciences in a research note on Monday, December 8th. Fourteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, WAVE Life Sciences has a consensus rating of “Moderate Buy” and an average price target of $32.56.

WAVE Life Sciences News Summary

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Wells Fargo kept an “overweight” rating on WVE and set a $27 price target (down from $29), which still implies substantial upside versus the current share price — a signal that some sell‑side analysts remain constructive on the company’s pipeline and long‑term prospects. The Fly: Wells Fargo price target note
• Positive Sentiment: Broader analyst coverage remains favorable — multiple firms have upgraded or raised targets in recent months and the consensus remains skewed toward Buy/Outperform, supporting potential upside if clinical progress continues. MarketBeat analyst roundup
• Neutral Sentiment: Institutional ownership is very high (~90%), which means large holders dominate supply — that can both support the stock during positive news and amplify moves when those holders change positions.
• Negative Sentiment: Multiple insiders sold shares on Feb 9 (CEO Paul Bolno, CFO Kyle Moran, and other officers/directors), executing sizable sales at roughly $13.45 per share — the cluster of top‑executive sales is being viewed negatively by the market as a potential signal of near‑term insider liquidity. InsiderTrades alert
• Negative Sentiment: WAVE’s last reported quarter missed estimates (EPS and revenue) and the company remains unprofitable with wide negative margins — ongoing cash burn and execution risk keep the shares sensitive to clinical and revenue updates. MarketBeat: earnings summary

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.